RELATIONSHIP BETWEEN MOOD DISORDERS AND THYROID CHANGES

The thyroid gland, located at the base of the neck, produces hormones that regulate the body's metabolism, growth and development. Changes in the levels of these hormones, such as hypothyroidism (low production) and hyperthyroidism (high production), can have a significant impact on mental health, influencing the development of mood disorders. Studies demonstrate a strong association between thyroid dysfunction and disorders such as depression and bipolar disorder. In hypothyroidism, depressive symptoms may include fatigue, mental sluggishness, anhedonia, and weight gain. In hyperthyroidism, anxiety, insomnia and irritability are more frequent. The bidirectional relationship between thyroid and mood is complex and involves several mechanisms. Changes in thyroid hormone levels can affect brain neurotransmission, especially serotonin and dopamine, neurotransmitters directly related to mood. Furthermore, the hypothalamic-pituitary-thyroid axis, responsible for thyroid hormonal regulation, can also be influenced by psychological factors such as stress. Objective: To carry out a systematic review of the literature to evaluate the relationship between mood disorders and thyroid changes, investigating the prevalence of mood disorders in individuals with thyroid diseases, the underlying pathophysiological mechanisms and the impact of hormone replacement on mental health. Methodology: The review followed the PRISMA checklist guidelines. The PubMed, Scielo and Web of Science databases were searched using the following descriptors: "mood disorders", "hypothyroidism", "hyperthyroidism", "thyroid" and "mental health". Articles published in the last 10 years were selected. Inclusion criteria: studies that evaluate the relationship between mood disorders and thyroid diseases; Human studies; Published in Portuguese, English or Spanish; Published in the last 10 years. Exclusion: Animal studies; Studies with inadequate methodological designs; Studies that do not evaluate the relationship between mood and thyroid. Results: 15 studies were selected. The review identified that the prevalence of mood disorders is significantly higher in individuals with thyroid disease than in the general population. Hypothyroidism is associated with depression, while hyperthyroidism is more related to anxiety. The pathophysiological mechanisms underlying the relationship between mood and thyroid are complex and involve changes in cerebral neurotransmission, the hypothalamic-pituitary-thyroid axis and the response to stress. Adequate hormone replacement for thyroid disease can significantly improve symptoms of mood disorders in many cases. Conclusions: The systematic review confirmed the strong association between mood disorders and thyroid changes. Thyroid dysfunction can be a risk factor for the development of mood disorders, and adequate hormone replacement can be an important therapeutic tool.The thyroid gland, located at the base of the neck, produces hormones that regulate the body's metabolism, growth and development. Changes in the levels of these hormones, such as hypothyroidism (low production) and hyperthyroidism (high production), can have a significant impact on mental health, influencing the development of mood disorders. Studies demonstrate a strong association between thyroid dysfunction and disorders such as depression and bipolar disorder. In hypothyroidism, depressive symptoms may include fatigue, mental sluggishness, anhedonia, and weight gain. In hyperthyroidism, anxiety, insomnia and irritability are more frequent. The bidirectional relationship between thyroid and mood is complex and involves several mechanisms. Changes in thyroid hormone levels can affect brain neurotransmission, especially serotonin and dopamine, neurotransmitters directly related to mood. Furthermore, the hypothalamic-pituitary-thyroid axis, responsible for thyroid hormonal regulation, can also be influenced by psychological factors such as stress. Objective: To carry out a systematic review of the literature to evaluate the relationship between mood disorders and thyroid changes, investigating the prevalence of mood disorders in individuals with thyroid diseases, the underlying pathophysiological mechanisms and the impact of hormone replacement on mental health. Methodology: The review followed the PRISMA checklist guidelines. The PubMed, Scielo and Web of Science databases were searched using the following descriptors: "mood disorders", "hypothyroidism", "hyperthyroidism", "thyroid" and "mental health". Articles published in the last 10 years were selected. Inclusion criteria: studies that evaluate the relationship between mood disorders and thyroid diseases; Human studies; Published in Portuguese, English or Spanish; Published in the last 10 years. Exclusion: Animal studies; Studies with inadequate methodological designs; Studies that do not evaluate the relationship between mood and thyroid. Results: 15 studies were selected. The review identified that the prevalence of mood disorders is significantly higher in individuals with thyroid disease than in the general population. Hypothyroidism is associated with depression, while hyperthyroidism is more related to anxiety. The pathophysiological mechanisms underlying the relationship between mood and thyroid are complex and involve changes in cerebral neurotransmission, the hypothalamic-pituitary-thyroid axis and the response to stress. Adequate hormone replacement for thyroid disease can significantly improve symptoms of mood disorders in many cases. Conclusions: The systematic review confirmed the strong association between mood disorders and thyroid changes. Thyroid dysfunction can be a risk factor for the development of mood disorders, and adequate hormone replacement can be an important therapeutic tool

IMPACT OF THYROID DYSFUNCTION IN PATIENTS WITH ATRIAL FIBRILLATION

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in clinical practice, affecting approximately 2% of the general population and increasing the risk of stroke, heart failure and mortality. AF is often associated with several clinical conditions, including thyroid dysfunction, which can alter metabolism, function and cardiac structure. Thyroid dysfunction can be classified as hypothyroidism (low production of thyroid hormones) or hyperthyroidism (excess production of thyroid hormones), both of which can cause or worsen AF. The mechanism by which thyroid dysfunction affects AF is complex and involves electrophysiological, hemodynamic, inflammatory and structural changes in the atria. Appropriate diagnosis and treatment of thyroid dysfunction can improve AF control and reduce thromboembolic and hemorrhagic complications. However, the prevalence, incidence, risk factors, prognosis and management of AF in patients with thyroid dysfunction are still controversial topics in the literature. Objective: to evaluate the impact of thyroid dysfunction in patients with AF, addressing the following aspects: epidemiology, pathophysiology, diagnosis, treatment and clinical outcomes. Methodology: This review was carried out in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) protocol. The PubMed, Scielo and Web of Science databases were searched, using the following descriptors: "atrial fibrillation", "thyroid dysfunction", "hypothyroidism", "hyperthyroidism" and "thyrotoxicosis". Articles published in the last 10 years, in Portuguese, English or Spanish, that addressed the proposed topic were included. Articles that were not original, did not have sufficient data or were not relevant to the research question were excluded. Results: 18 studies were selected. The diagnosis of AF in patients with thyroid dysfunction requires confirmation of the heart rhythm by electrocardiogram (ECG) and assessment of serum thyroid hormone levels (TSH, free T4 and free T3). Treatment of AF in patients with thyroid dysfunction aims to restore and maintain sinus rhythm, control ventricular rate, prevent thromboembolic events, and correct thyroid dysfunction. Therapeutic options include antiarrhythmic drugs, antithyroid drugs, anticoagulant drugs, electrical cardioversion, catheter ablation, and surgical thyroid treatment. The clinical outcomes of AF in patients with thyroid dysfunction are influenced by the type, severity and duration of thyroid dysfunction, as well as rhythm, frequency and anticoagulation control. AF in patients with thyroid dysfunction is associated with a higher risk of arrhythmia recurrence, heart failure, stroke and mortality. Conclusion: Thyroid dysfunction is a frequent and important clinical condition in patients with AF, as it can cause or worsen arrhythmia, as well as increase the risk of complications. Appropriate diagnosis and treatment of thyroid dysfunction can improve AF control and reduce adverse outcomes. However, there are still gaps in knowledge about the epidemiology, pathophysiology, prognosis and management of AF in patients with thyroid dysfunction, which require further studies of high quality and clinical relevance.Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in clinical practice, affecting approximately 2% of the general population and increasing the risk of stroke, heart failure and mortality. AF is often associated with several clinical conditions, including thyroid dysfunction, which can alter metabolism, function and cardiac structure. Thyroid dysfunction can be classified as hypothyroidism (low production of thyroid hormones) or hyperthyroidism (excess production of thyroid hormones), both of which can cause or worsen AF. The mechanism by which thyroid dysfunction affects AF is complex and involves electrophysiological, hemodynamic, inflammatory and structural changes in the atria. Appropriate diagnosis and treatment of thyroid dysfunction can improve AF control and reduce thromboembolic and hemorrhagic complications. However, the prevalence, incidence, risk factors, prognosis and management of AF in patients with thyroid dysfunction are still controversial topics in the literature. Objective: to evaluate the impact of thyroid dysfunction in patients with AF, addressing the following aspects: epidemiology, pathophysiology, diagnosis, treatment and clinical outcomes. Methodology: This review was carried out in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) protocol. The PubMed, Scielo and Web of Science databases were searched, using the following descriptors: "atrial fibrillation", "thyroid dysfunction", "hypothyroidism", "hyperthyroidism" and "thyrotoxicosis". Articles published in the last 10 years, in Portuguese, English or Spanish, that addressed the proposed topic were included. Articles that were not original, did not have sufficient data or were not relevant to the research question were excluded. Results: 18 studies were selected. The diagnosis of AF in patients with thyroid dysfunction requires confirmation of the heart rhythm by electrocardiogram (ECG) and assessment of serum thyroid hormone levels (TSH, free T4 and free T3). Treatment of AF in patients with thyroid dysfunction aims to restore and maintain sinus rhythm, control ventricular rate, prevent thromboembolic events, and correct thyroid dysfunction. Therapeutic options include antiarrhythmic drugs, antithyroid drugs, anticoagulant drugs, electrical cardioversion, catheter ablation, and surgical thyroid treatment. The clinical outcomes of AF in patients with thyroid dysfunction are influenced by the type, severity and duration of thyroid dysfunction, as well as rhythm, frequency and anticoagulation control. AF in patients with thyroid dysfunction is associated with a higher risk of arrhythmia recurrence, heart failure, stroke and mortality. Conclusion: Thyroid dysfunction is a frequent and important clinical condition in patients with AF, as it can cause or worsen arrhythmia, as well as increase the risk of complications. Appropriate diagnosis and treatment of thyroid dysfunction can improve AF control and reduce adverse outcomes. However, there are still gaps in knowledge about the epidemiology, pathophysiology, prognosis and management of AF in patients with thyroid dysfunction, which require further studies of high quality and clinical relevance

International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module

We report the results of an International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2007-December 2012 in 503 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study using the Centers for Disease Control and Prevention's (CDC) U.S. National Healthcare Safety Network (NHSN) definitions for device-associated health care–associated infection (DA-HAI), we collected prospective data from 605,310 patients hospitalized in the INICC's ICUs for an aggregate of 3,338,396 days. Although device utilization in the INICC's ICUs was similar to that reported from ICUs in the U.S. in the CDC's NHSN, rates of device-associated nosocomial infection were higher in the ICUs of the INICC hospitals: the pooled rate of central line–associated bloodstream infection in the INICC's ICUs, 4.9 per 1,000 central line days, is nearly 5-fold higher than the 0.9 per 1,000 central line days reported from comparable U.S. ICUs. The overall rate of ventilator-associated pneumonia was also higher (16.8 vs 1.1 per 1,000 ventilator days) as was the rate of catheter-associated urinary tract infection (5.5 vs 1.3 per 1,000 catheter days). Frequencies of resistance of Pseudomonas isolates to amikacin (42.8% vs 10%) and imipenem (42.4% vs 26.1%) and Klebsiella pneumoniae isolates to ceftazidime (71.2% vs 28.8%) and imipenem (19.6% vs 12.8%) were also higher in the INICC's ICUs compared with the ICUs of the CDC's NHSN

Brazilian Flora 2020: Leveraging the power of a collaborative scientific network

International audienceThe shortage of reliable primary taxonomic data limits the description of biological taxa and the understanding of biodiversity patterns and processes, complicating biogeographical, ecological, and evolutionary studies. This deficit creates a significant taxonomic impediment to biodiversity research and conservation planning. The taxonomic impediment and the biodiversity crisis are widely recognized, highlighting the urgent need for reliable taxonomic data. Over the past decade, numerous countries worldwide have devoted considerable effort to Target 1 of the Global Strategy for Plant Conservation (GSPC), which called for the preparation of a working list of all known plant species by 2010 and an online world Flora by 2020. Brazil is a megadiverse country, home to more of the world's known plant species than any other country. Despite that, Flora Brasiliensis, concluded in 1906, was the last comprehensive treatment of the Brazilian flora. The lack of accurate estimates of the number of species of algae, fungi, and plants occurring in Brazil contributes to the prevailing taxonomic impediment and delays progress towards the GSPC targets. Over the past 12 years, a legion of taxonomists motivated to meet Target 1 of the GSPC, worked together to gather and integrate knowledge on the algal, plant, and fungal diversity of Brazil. Overall, a team of about 980 taxonomists joined efforts in a highly collaborative project that used cybertaxonomy to prepare an updated Flora of Brazil, showing the power of scientific collaboration to reach ambitious goals. This paper presents an overview of the Brazilian Flora 2020 and provides taxonomic and spatial updates on the algae, fungi, and plants found in one of the world's most biodiverse countries. We further identify collection gaps and summarize future goals that extend beyond 2020. Our results show that Brazil is home to 46,975 native species of algae, fungi, and plants, of which 19,669 are endemic to the country. The data compiled to date suggests that the Atlantic Rainforest might be the most diverse Brazilian domain for all plant groups except gymnosperms, which are most diverse in the Amazon. However, scientific knowledge of Brazilian diversity is still unequally distributed, with the Atlantic Rainforest and the Cerrado being the most intensively sampled and studied biomes in the country. In times of “scientific reductionism”, with botanical and mycological sciences suffering pervasive depreciation in recent decades, the first online Flora of Brazil 2020 significantly enhanced the quality and quantity of taxonomic data available for algae, fungi, and plants from Brazil. This project also made all the information freely available online, providing a firm foundation for future research and for the management, conservation, and sustainable use of the Brazilian funga and flora

Measurement of inclusive and differential cross sections of single top quark production in association with a W boson in proton-proton collisions at s\sqrt{s} = 13.6 TeV

International audienceThe first measurement of the inclusive and normalised differential cross sections of single top quark production in association with a W boson in proton-proton collisions at a centre-of-mass energy of 13.6 TeV is presented. The data were recorded with the CMS detector at the LHC in 2022, and correspond to an integrated luminosity of 34.7 fb$^{-1}$. The analysed events contain one muon and one electron in the final state. For the inclusive measurement, multivariate discriminants exploiting the kinematic properties of the events are used to separate the signal from the dominant top quark-antiquark production background. A cross section of 82.3 $\pm$ 2.1 (stat) ${}^{+9.9}_{-9.7}$ (syst) $\pm$ 3.3 (lumi) pb is obtained, consistent with the predictions of the standard model. A fiducial region is defined according to the detector acceptance to perform the differential measurements. The resulting differential distributions are unfolded to particle level and show good agreement with the predictions at next-to-leading order in perturbative quantum chromodynamics

Search for bottom quark associated production of the standard model Higgs boson in final states with leptons in proton-proton collisions at s\sqrt{s} = 13 TeV

International audienceThis Letter presents the first search for bottom quark associated production of the standard model Higgs boson, in final states with leptons. Higgs boson decays to pairs of tau leptons and pairs of leptonically decaying W bosons are considered. The search is performed using data collected from 2016 to 2018 by the CMS experiment in proton-proton collisions at a centre-of-mass energy of 13 TeV, corresponding to an integrated luminosity of 138 fb${-1}$. Upper limits at the 95% confidence level are placed on the signal strength for Higgs boson production in association with bottom quarks; the observed (expected) upper limit is 3.7 (6.1) times the standard model prediction

Search for light long-lived particles decaying to displaced jets in proton-proton collisions at s\sqrt{s} = 13.6 TeV

International audienceA search for light long-lived particles decaying to displaced jets is presented, using a data sample of proton-proton collisions at a center-of-mass energy of 13.6 TeV, corresponding to an integrated luminosity of 34.7 fb$^{-1}$, collected with the CMS detector at the CERN LHC in 2022. Novel trigger, reconstruction, and machine-learning techniques were developed for and employed in this search. After all selections, the observations are consistent with the background predictions. Limits are presented on the branching fraction of the Higgs boson to long-lived particles that subsequently decay to quark pairs or tau lepton pairs. An improvement by up to a factor of 10 is achieved over previous limits for models with long-lived particle masses smaller than 60 GeV and proper decay lengths smaller than 1 m. The first constraints are placed on the fraternal twin Higgs and folded supersymmetry models, where the lower bounds on the top quark partner mass reach up to 350 GeV for the fraternal twin Higgs model and 250 GeV for the folded supersymmetry model

Measurement of inclusive and differential cross sections of single top quark production in association with a W boson in proton-proton collisions at s\sqrt{s} = 13.6 TeV

International audienceThe first measurement of the inclusive and normalised differential cross sections of single top quark production in association with a W boson in proton-proton collisions at a centre-of-mass energy of 13.6 TeV is presented. The data were recorded with the CMS detector at the LHC in 2022, and correspond to an integrated luminosity of 34.7 fb$^{-1}$. The analysed events contain one muon and one electron in the final state. For the inclusive measurement, multivariate discriminants exploiting the kinematic properties of the events are used to separate the signal from the dominant top quark-antiquark production background. A cross section of 82.3 $\pm$ 2.1 (stat) ${}^{+9.9}_{-9.7}$ (syst) $\pm$ 3.3 (lumi) pb is obtained, consistent with the predictions of the standard model. A fiducial region is defined according to the detector acceptance to perform the differential measurements. The resulting differential distributions are unfolded to particle level and show good agreement with the predictions at next-to-leading order in perturbative quantum chromodynamics